Know Cancer

or
forgot password

DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Head and Neck Neoplasms, Recurrence, Neoplasms, Second Primary

Thank you

Trial Information

DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer


Inclusion Criteria:



- Incurable primary or second primary head and neck cancer

- Speaks and reads Danish

- Capable of filling out questionnaires for at leas two months after radiotherapy

- Age>=18 years

- Expected survival> 3months

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Frequency and intensity of symptoms before and after radiotherapy (EORTC C30 and H&N35 questionnaires and CTC AE 3.0 toxicity scores)

Outcome Time Frame:

11 mths

Safety Issue:

No

Principal Investigator

Kenneth Jensen, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

DAHANCA (Danish Head and Neck Cancer Group)

Authority:

Denmark: The Regional Committee on Biomedical Research Ethics

Study ID:

DAHANCA 20

NCT ID:

NCT00400426

Start Date:

November 2006

Completion Date:

June 2012

Related Keywords:

  • Head and Neck Neoplasms
  • Recurrence
  • Neoplasms, Second Primary
  • Palliative radiotherapy
  • Recurrent
  • Head and neck Neoplasm
  • Quality of life
  • Neoplasms
  • Head and Neck Neoplasms
  • Recurrence
  • Neoplasms, Second Primary

Name

Location